Nearly 300 years after the first Mi'kmaq treaties were signed, people gathered on Tuesday in Halifax and elsewhere in Nova Scotia to mark Treaty Day. Since 1986, Oct. 1 has been Treaty Day in the ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity ... It happened in the Loblaws parking lot in College Square, when she was approached by ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of major adverse cardiovascular events (MACE) in patients with type 2 ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity. These new types of therapies could be more economical than ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.

Novo Nordisk is a great business ... or historical increases can tell us a lot. However, none of that matters if the corporation's underlying business is in shambles. Investors were recently ...

Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments, with indicators of continued demand and sales growth. The firm's profit margin and expected EPS growth beats ...

Pharmaceutical giant Novo ... Novo Nordisk's, but is that enough? A company's forward yield, dividend per share, frequency of dividend payment, or historical increases can tell us a lot.